Customer- Facing
Industries
F
or more than three decades, we have been publishing the annual Quest Diagnostics Drug Testing
Index™ (DTI), featuring data and trends for workforce drug testing in the United States. During this time, we have noted changes in drug positivity and regional trends. Today, our industry faces state marijuana legalization and an opioid crisis that has been declared a national health emergency, claiming the lives of an estimated 130 Americans each day who overdose on opioids. In the DTI, we make distinctions by
specimen type and examine three categories of workers: the federally-mandated, safety-sensitive workforce; the general U.S. workforce; and the combined U.S. workforce. However, one element that was historically absent from our annual reporting was drug positivity by industry sector. Due in large part to requests from industry partners and the media, we undertook a major, time-intensive database initiative during the past 18 months to classify tens of thousands of customer companies by industry sector.
Millions of Urine Drug Test Results
Our new, enhanced DTI reporting features industry positivity rates based upon classifications of our customer data by industry sector using the North American Industry Classification System (NAICS). Te data in our industry reporting feature laboratory-based general U.S. workforce urine drug test results for routine drug testing prior to evaluation by a medical review officer. Rehabilitation, criminal justice, point of collection confirmation, and federally- mandated, safety-sensitive testing data were excluded. In the end, the industry- classified data accounted for more than 50% of our general U.S. workforce urine testing volume, representing more than three million annual drug test results.
www.datia.org
datia focus
9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
